Osteoarthritis is a common chronic and degenerative disease among adults. A group of experts estimated the disease’s burden spanning two decades and the projection of burden to 2050.
Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...
In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.
In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...
Researchers examined the efficacy and safety of a humanized monoclonal antibody for the treatment of active psoriatic arthritis in some patient populations.
The researchers evaluated the impact of antirheumatic treatment in women who are pregnant with psoriatic arthritis and how such treatment affects pregnancy outcomes.
